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Background: The coinhibitory receptor Programmed Death-1 (PD-1) inhibits effector functions of activated T cells
and prevents autoimmunity, however, cancer hijack this pathway to escape from immune attack. The costimulatory
receptor glucocorticoid-induced TNFR related protein (GITR) is up-regulated on activated T cells and increases their
proliferation, activation and cytokine production. We hypothesize that concomitant PD-1 blockade and GITR triggering
would synergistically improve the effector functions of tumor-infiltrating T cells and increase the antitumor immunity.
In present study, we evaluated the antitumor effects and mechanisms of combined PD-1 blockade and GITR triggering
in a clinically highly relevant murine ID8 ovarian cancer model.
Methods: Mice with 7 days-established peritoneal ID8 ovarian cancer were treated intraperitoneally (i.p.) with either
control, anti-PD-1, anti-GITR or anti-PD-1/GITR monoclonal antibody (mAb) and their survival was evaluated; the
phenotype and function of tumor-associated immune cells in peritoneal cavity of treated mice was analyzed by flow
cytometry, and systemic antigen-specific immune response was evaluated by ELISA and cytotoxicity assay.
Results: Combined anti-PD-1/GITR mAb treatment remarkably inhibited peritoneal ID8 tumor growth with 20% of mice
tumor free 90 days after tumor challenge while treatment with either anti-PD-1 or anti-GITR mAb alone exhibited little
antitumor effect. The durable antitumor effect was associated with a memory immune response and conferred by CD4+
cells and CD8+ T cells. The treatment of anti-PD-1/GITR mAb increased the frequencies of interferon-γ-producing
effector T cells and decreased immunosuppressive regulatory T cells and myeloid-derived suppressor cells, shifting an
immunosuppressive tumor milieu to an immunostimulatory state in peritoneal cavity. In addition, combined
treatment of anti-PD-1/GITR mAb mounted an antigen-specific immune response as evidenced by antigen-specific
IFN-γ production and cytolytic activity of spleen cells from treated mice. More importantly, combined treatment
of anti-PD-1/GITR mAb and chemotherapeutic drugs (cisplatin or paclitaxel) further increased the antitumor
efficacy with 80% of mice obtaining tumor-free long-term survival in murine ID8 ovarian cancer and 4 T1 breast
cancer models.
Conclusions: Combined anti-PD-1/GITR mAb treatment induces a potent antitumor immunity, which can be further
promoted by chemotherapeutic drugs. A combined strategy of anti-PD-1/GITR mAb plus cisplatin or paclitaxel should
be considered translation into clinic.
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Epithelial ovarian carcinoma (EOC) is the most lethal
gynecological tumor in women, with 22,280 new cases
and 15,460 deaths estimated in the United States for
2012 [1]. Five-year overall survival is approximately 45%,
and, even with modern surgical and chemotherapeutic
strategies, most cases with advanced disease relapse and
succumb to the disease [2,3]. Thus, it is major requisite
to develop novel strategies for improving the outcomes
of ovarian cancer.
Emerging evidence indicates that EOC should be
amenable to the immunotherapy [4]. Previous studies
show that EOC cells express many tumor-associated
antigens against which specific immune responses can
be detected [5-9]. The pioneer studies by Coukos and
colleagues further indicate immune response in tumor
tissue is associated with clinical outcome of patients
with EOC as evidenced by the close correlation between
patient survival and tumor infiltration with CD3+ T cells
in the large annotated clinical samples [10]. In addition,
in patients with EOC metastases are frequently restricted
to the peritoneal cavity where the tumor is directly
accessible, obviating the need for systemic delivery of
immune-modulatory agents [11]. Despite the abundant
evidence supporting EOC immunotherapy, clinical success
with immune-based therapies for EOC has generally been
modest [12].
Programmed Death 1 (PD-1) protein is a key co-
inhibitory receptor which is inducibly expressed on acti-
vated T cells, B cells, macrophages, dendritic cells (DC)
and monocytes. PD-1 has been shown to inhibit both
adaptive and innate immune response when engagement
of its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC), which
are expressed by tumor cells, stromal cells, or both
[13,14]. PD-L1 is the primary PD-1 ligand that is up-
regulated in solid tumors, where it can inhibit cytokine
production and the cytolytic activity of PD-1+ tumor-
infiltrating CD4+ and CD8+ T cells [15,16]. Blockade of
PD-1/PD-L1 interaction induces potent antitumor effects
in animal models [14,17,18]; furthermore, recent clinical
trials show that monoclonal antibodies (mAbs) specific for
PD-1 and PD-L1 mount an impressive antitumor effect in
several types of solid tumors with complete regression
observed in some patients [19-21], demonstrating PD-1/
PD-L1 pathway as a highly promising target for cancer
immunotherapy.
Glucocorticoid-induced TNFR related protein (GITR;
a.k.a. TNFRSF18) is a co-stimulatory molecule of TNF
receptor family expressed on activated T cells, B cells,
NK and myeloid cells and regulatory T cells (Treg) [22].
As a co-stimulatory molecule, GITR engagement increa-
ses proliferation, activation, and cytokine production
of CD4+ and CD8+ T cells [22]. GITR-specific agonis-
tic mAbs or recombinant GITR ligand (GITRL) fusionproteins have been shown to induce tumor regression
in vivo through the activation of CD4+ T cells, CD8+
T cells and NK cells in several tumor models [23-25].
In addition, GITR triggering can also abrogate the im-
munosuppressive activity of natural Treg [26]; however,
evidence indicates that the expansion of CD4+ effector
cells, rather than Treg inhibition, is the primary mechan-
ism underlying the antitumor effects mediated by GITR-
targeting mAbs [27]. A humanized GITR-targeting mAb
(TRX518) is currently being evaluated in Phase I clinical
trials treating patients with late-stage melanoma [28].
Although antagonist PD-1 or agonistic GITR mAbs
can promote the rejection of some murine tumors, how-
ever, poorly immunogenic tumors such as ID8 ovarian
cancer do not respond to single immunomodulating
mAb therapy [29]. We hypothesized that combined
PD-1 blockade and GITR triggering could synergistically
potentiate the antitumor immune response. In this study,
using ID8 murine ovarian cancer model, we evaluated the
antitumor effects and underlying mechanisms of com-
bined anti-PD-1/GITR mAb treatment.
Methods
Mice
Female C57BL (6–8 week old) were purchased from the
Model Animal Research Center of Nanjing University.
Animal use was approved by the Institutional Review
Board of Jindu Hospital, Nanjing, China.
Cell culture
ID8, a clone of the MOSEC ovarian carcinoma of
C57BL/6 origin was a gift from Dr. George Coukos
(University of Pennsylvania, Philadelphia, USA). Murine
4 T1 breast cancer cells (BALB/c background) and T cell
lymphoma EL4 cells (C57BL/6 background) were kindly
sent by Dr. Pu Liu (University of Washington, WA, USA).
Tumor cells were cultured in the complete DMEM
medium supplemented with 10% FBS (Thermo Scientific,
Rockford, IL), 100 U/mL penicillin and 100 μg/mL strep-
tomycin before cell suspensions were prepared and trans-
planted to mice. The EL4 cells and splenocytes were
maintained in a complete medium of RPMI-1640 supple-
mented with 10% FBS, 25 mM HEPES, 2 mM glutamine,
100 U/mL penicillin and 100 μg/mL streptomycin.
Reagents
Therapeutic anti-GITR (Clone DTA-1; Catalog#:BE0063),
anti-PD-1 (Clone RMP1-14; Catalog#BE0146), anti-CD4
(Clone GK1.5; Catalog#:BE0003-1), anti-CD8 (Clone 2.43;
Catalog#:BE0061), anti-NK1.1 (Clone PK136; Catalog#:
BE0036) and control rat IgG (Clone 2A3; Catalog#:
BE0089) monoclonal antibodies (mAb) were purchased
from BioXcell (West Lebanon, NH). Antibodies used for
flow cytometry were purchased from Tianjing Sungene
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CA). H-2Db-restricted mesothelin-derived (MESO406-414:
GQKMNAQAI) or control lymphocytic choriomeningi-
tis virus (LCMV) glycoprotein (GP)-derived (GP33-41:
KAVYNFATC) epitope peptide were synthesized by
GenScript (Beijing, China) and more than 95% of purity
were confirmed by HPLC. Peptides were reconstituted
in DMSO with final concentration of 10 mg/mL.
Animal experiments
Mice (10 mice/group) were transplanted intraperitoneally
(i.p.) with 5 × 106 ID8 cells in 0.1 mL of PBS on day 1. On
days 8, 11 and 15, mice received the i.p. injection of
250 μg of control, anti-PD-1, anti-GITR or anti-PD-1/
GITR mAb in 250 μL of PBS. For combined mAb/cis-
platin or paclitaxel therapy experiments, mice (10 mice/
group) bearing 8 days established ID8 ovarian cancer were
first pretreated with a dose of cisplatin (10 mg/kg in
100 μL PBS) or paclitaxel (10 mg/kg in 100 μL PBS)
followed by three doses of control or anti-PD-1/GITR
mAb at the schedule described above starting on day 9.
Long-term surviving mice from combined anti-PD-1/
GITR treatment were rechallenged i.p. with 5 × 106 ID8
cells The mice were weighed every other day and checked
for the clinical sign of swollen bellies indicative of ascites
formation and for the evidence of toxicity such as res-
piratory distress, mobility, weight loss, diarrhea, hunched
posture, and failure to eat while histopathology was con-
ducted on major organs (i.e., liver, kidney, intestines,
lungs, and colon). Mice were euthanized when they devel-
oped ascites and had a weight increase > 30% of original
weight on day 1. For combined therapy experiments in
the 4 T1 breast cancer model, mice (5/group) were trans-
planted subcutaneously (s.c.) with 5 × 105 4 T1 cells in
0.1 mL of PBS on day 1. On days 8, mice were intratumo-
rally (i.t.) treated with cispaltin or paclitaxel followed by
mAb using the dose/schedule described in ID8 model.
Two perpendicular diameters of s.c. tumors were mea-
sured every other day using a caliper and tumor volumes
were calculated according to the formula: 1/2 × (length) ×
(width)2. Mice were sacrificed when they seemed mori-
bund or their tumors reached 10 mm in diameter. The
survival of mice was recorded and overall survival was cal-
culated. For lymphocyte depleting experiments, mice were
injected i.p. with 500 μg of mAb against CD8, CD4, or
NK1.1, 1 day before and two days after tumor challenge,
followed by injection of 250 μg every 5 days throughout
the experiment. The efficacy of cell depletion was verified
by flow cytometric analysis of lymphocyte subsets in per-
ipheral blood (data not shown).
Evaluation of tumor-associated immune cells (TAC)
Tumor-bearing mice were euthanized 7 days after the last
treatment described as in animal experiments. To obtainTAC, 3 ml PBS was injected into the peritoneal cavity of
mice with ID8 tumors immediately after euthanasia, their
belly was massaged and the fluid was removed, filtered
through a 70 μM cell strainer (BD Biosciences), washed
and resultant peritoneal cells (including immune cells and
tumor cells) were subjected to further analysis.
For flow cytometric staining, single cell suspensions of
peritoneal cells were washed with FACS staining buffer
and incubated with mouse Fc receptor binding inhibitor
(eBioscience) for 10 minutes before staining with mAbs
(eBioscience) against mouse CD45 (clone 30-F11), CD3
(clone 145-2C11), CD4 (clone GK1.5), CD8 (clone 53–6.7),
CD19 (clone eBio1D3), CD11b (clone M1/70), Gr-1 (clone
RB6-8C5), CD44 (clone 1 M7) and CD62L (clone MEL-14)
for 30 minutes. For intracellular staining of FoxP3 (clone
FJK-16 s), cells were fixed, permeabilized, and stained
following the instruction of Cytofix/Cytoperm kit (BD
Bioscience). For intracellular staining of IFN-γ (clone
XMG1.2), cells were restimulated in vitro with 50 ng/ml
PMA and 1 μg/ml ionomycin for 4 hours prior to the
analysis of IFN-γ secretion in CD4+ or CD8+ subsets. Flow
cytometry was performed using FACSCalibur (BD Bio-
sciences) and the lymphocyte population was selected by
gating CD45-positive cells. The data were analyzed using
Flow Jo software (Tree Star, Ashland, OR). All flow cytom-
etry experiments were performed at least 3 times.
Evaluation of antigen-specific immune response
Isolated splenocytes from treated mice were cultured in
the presence of 10 μg/mL H-2Db-restricted mesothelin-
derived (MESO406-414) or LCMV-GP (GP33-41) epitope
peptide for 3 days. IFN-γ concentration in the superna-
tants was determined by Mouse IFN-γ Quantikine ELISA
Kit (R&D systems).
For mesothelin-specific CTL assays, effector cells were
obtained by coculturing 5 × 106 splenocytes with 5 × 105
UV-irradiated ID8 cells for 4 days. Peptide-pulsed EL4
target cells were generated by adding 10 μg/ml of peptide
and incubating for 4 hours. CTL activity was measured
using the CytoTox96 Non-Radioactive Cytotoxicity Assay
kit (Promega, Madison, WI) following the manufacturer’s
instructions. In brief, target cells were incubated with
varying numbers of effector cells for about 4 hours, and
supernatants were then analyzed for lactate dehydrogen-
ase release. The results are expressed as percent specific
lysis, calculated as (Experimental release-Spontaneous re-
lease/Total release-Spontaneous release) × 100.
Statistics
Results were expressed as mean ± SEM. All statistical
analyses were performed using GraphPad Prism 5.
Student’s t test was used to compare the statistical
difference between two groups and one-way ANOVA
was used to compare three or more groups. Survival
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evaluated with the log-rank test with Bonferroni correc-
tion. Significant differences were accepted at p < 0.05.
Results
Combined anti-PD-1/GITR mAb treatment induced potent
antitumor effects in ID8 ovarian cancer
We first assessed the antitumor effects of either single
or combined anti-PD-1/GITR mAb in murine ID8
ovarian cancer, a highly clinical relevant model with
ascites formation and metastases in peritoneal cavity
(Figure 1A). Group of C57BL/6 mice were i.p. trans-
planted with 5 × 106 ID8 cells on day 1 and then were
treated with i.p. injection of control, anti-PD-1, anti-
GITR or anti-PD-1/GITR mAb on day 8, 11 and 15.
Control mAb-treated mice developed ascites about
30 days after tumor challenge and had to be sacrificed.
Although either single anti-PD-1 or anti-GITR mAb
exhibited little antitumor effect, combined anti-PD-1/
GITR mAb treatment significantly prolonged overall sur-
vival time of mice (Figure 1B; median survival time 31.50,
34.00, 33.00 or >75.00 days for control, anti-PD-1,
anti-GITR or anti-PD-1/GITR mAb group respectively;
p < 0.01, combined mAb compared to single or control
mAb) with 20% (2 out of 10 mice) of mice remaining
tumor-free (confirmed by laparotomy) 90 days after tumor
challenge (Figure 1C). The weight of tumor masses fromFigure 1 Treatment of combined anti-PD-1/GITR mAb induced tumor
The typical presentation of ID8 ovarian cancer in C57BL/6 mice. The left an
tumor mass in peritoneal cavity of mice respectively. B, Mice (10 mice/grou
with 250 μg of control, anti-PD-1, anti-GITR and anti-PD-1/GITR mAb on day 8
C, Overall survival of mice was recorded. D, The peritoneal tumor masses wer
mouse. E, Long-term surviving (90 days after first tumor challenge) mice from
their overall survival was recorded. Naïve mice were challenged with ID8 cells
mAb were also injected with an anti-CD4, anti-CD8, anti-NK1.1, or control mA
tumor challenge followed by injection of 200 μg every 5 days thereafter for th
Data are representative of 2 independent experiments for B-E. **P < 0.05, ***Pmice treated with combined mAb also greatly decreased
compared with that from control or single mAb treated
mice (Figure 1D). A repeat of the experiment gave similar
results (data not shown). Long-term surviving mice from
first tumor challenge (90 days after first challenge), but
not naïve mice, were resistant to a subsequent rechallenge
i.p. with ID8 cells (Figure 1E), indicating that combined
anti-PD-1/GITR mAb treatment mounted an antitumor
memory immune response in mice. Cell depleting experi-
ments showed that tumor protection was dependent on
the CD4+ and CD8+ T cells as removal of CD4+ or CD8+
T cells abrogated the antitumor effect conferred by anti-
PD-1/GITR mAb treatment (Figure 1F).
Combined anti-PD-1/GITR mAb treatment shifted an
immunosuppressive to an immunostimulatory tumor
milieu
To define the immune mechanisms of the synergistic
antitumor effects of combined PD-1 blockade and GITR
triggering, we analyzed the phenotype and function of
tumor-associated immune cells (TAC) harvested from
peritoneal cavity of treated mice 7 days after last mAb
injection. Compared with control or single mAb, com-
bined mAb significantly increased the percentages of
effector CD4+FoxP3- T cells (mean value 7.70%, 7.78%,
11.94% and 31.50% for control, anti-PD-1, anti-GITR
and anti-PD-1/GITR group respectively; p < 0.01) and-specific long-lasting immunity against ID8 ovarian cancer. A,
d right picture shows the macroscopic appearance of ascites and ID8
p) were transplanted i.p. with 5 × 106 ID8 cells on day 1 and treated
, 11 and 15. Mean survival time of tumor-bearing mice was calculated.
e weighed when mice were euthanized with each dot representing each
combined mAb treatment group were rechallenged with ID8 cells and
as control. F, Mice (5 mice/group) treated with combined anti-PD-1/GITR
b with 500 μg of each mAb per mouse 1 day before and two days after
e duration of the experiments and their overall survival were recorded.
< 0.001, combined mAb vs control or single mAb.
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and 41.04%; p < 0.05) and decreased the frequency of
CD4+FoxP3+ regulatory T cells (Treg; mean value
9.72%, 10.44%, 6.44% and 2.54%; p < 0.05 and p < 0.01
compared to anti-GITR and control or anti-PD-1 respect-
ively) and CD11b+GR-1+ myeloid-derived suppressor cells
(MDSC; mean value 24.58%, 22.28%, 19.18% and 8.04%;
p < 0.05 and p < 0.01 compared to anti-GITR or anti-Figure 2 Subpopulation analysis of tumor-associated immune cells (T
with 5 × 106 ID8 cells on day 1 and treated with 250 μg of control, anti-PD
after last mAb injection, TAC from treated mice was analyzed by flow cytom
CD4+FoxP3-, CD8+, CD4+FoxP3+ Treg and CD11b+GR-1+ MDSC in TAC are s
CD8+ T cells to Treg and MDSC are shown in E, F, G and H respectively. Th
central memory in CD4+ and CD8+ T cells from TAC are shown in I and J resp
representative of 2 independent experiments, *P < 0.05, **P < 0.01.PD-1 and control respectively) in TAC on day 7 after
treatment (Figure 2A-D); These contrasting changes in
effector and immunosuppressive cells gave rise to the
significantly elevated ratios of both effector CD4+ and
CD8+ T cells to Treg and MDSC in peritoneal cavity of
mice receiving combined mAb treatment (Figure 2E-H).
With regards to individual mAb treatment, GITR en-
gagement modestly elevated the percentage of effectorAC) from treated mice. Mice (5 mice/group) were transplanted i.p.
-1, anti-GITR and anti-PD-1/GITR mAb on day 8, 11 and 15. Seven days
etry for various immune cell subpopulations. The percentages of
hown in A, B, C and D respectively. The ratios of both CD4+ and
e frequencies of CD44+CD62L- effector/memory and CD44+CD62L+
ectively. Each dot represents the data from each mouse and Data are
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frequencies of Treg and MDSC; however, single PD-1 had
little effect on these subsets. We also noted an increase in
absolute number of total peritoneal immune cells from 2
mAb treated mice (mean value (× 106/mouse): 3.8, 3.9, 4.2
and 6.5 for control, anti-PD-1, anti-GITR and anti-PD-1/
GITR group respectively; p < 0.05) and the changes in
absolute number of each subset had a similar trend to
their percentages (data not shown).
Analysis of CD44 and CD62L expression on CD4+ and
CD8+ T cells demonstrated that TAC from anti-PD-1/
GITR mAb treated mice contained significantly increa-
sed percentage of CD44+CD62L- effector/memory cells
(mean value 7.77%, 9.83%, 11.00% and 33.70% for CD4
cells; 17.93%, 22.10%, 26.50% and 53.30% for CD8 cells;
p < 0.05 for both cells) and CD44+CD62L+ central mem-
ory cells (31.00%, 41.20%, 43.13% and 54.17% for CD4
cells; 36.67% , 35.67%, 33.67% and 36.57% for CD8 cells;
p < 0.05 for CD4 cells) compared with that from control
or single mAb treated mice (Figure 3I, J), where we
could see more effector/memory cells or central memory
cells in respective CD8+ or CD4+ T cells from combin-
ation treatment.
Further functional analysis showed that significantly
elevated frequencies of IFN-γ-producing cells were seen
in tumor-associated CD4+ and CD8+ T cells from com-
bined mAb treated mice (Figure 3A). The representative
dotplots were shown in Figure 3B.
Together, the data indicate that PD-1 blockade and
GITR triggering synergistically creates higher ratios of
effector T cells to immunosuppressive cells in peritoneal
cavity of treated mice, which represents the shift of an
immunosuppressive tumor milieu to an immunosti-
mulatory state which is more permissive for immune
mediated tumor destruction.
Combined anti-PD-1/GITR mAb treatment mounted an
antigen-specific CTL response
We next evaluated the antigen-specific immune response
in treated mice. As ID8 cancer cells express the mesothe-
lin, a well-known tumor antigen [29,30], we harvested
splenocytes from treated mice, and cultured them in the
presence of 10 μg/mL of H-2Db-restricted mesothelin-
derived epitope peptide (MESO406–414) or control
GP33–41 epitope peptide for 3 days and assayed IFN-γ
secretion in culture supernatants by ELISA. As shown in
Figure 4A, splenocytes from combined mAb-treated mice
produced significantly higher levels of IFN-γ when sti-
mulated by the mesothelin epitope peptide compared to
control or single mAb-treated mice (P < 0.01). No IFN-γ
secretion were seen in the culture supernatants of spleno-
cytes from treated mice upon stimulation by control
GP33–41 epitope peptide, suggesting the elicitation of
mesothelin-specific immune response in combined mAbtreated mice. We further evaluated the antigen-specific
killing activity by splenocytes from treated mice. Spleno-
cytes were restimulated with UV-irradiated ID8 cells for
5 days before CTL assays were performed using EL4 cells
pulsed with MESO406–414 or GP33–41 epitope peptide
as target cells. As shown in Figure 4B and 4C, splenocytes
from anti-PD-1/GITR treated mice, but not control or
single mAb treated mice, exhibited a prominent cytotox-
icity against EL4 cell pulsed with MESO406–414 but
not GP33–41 epitope peptide, suggesting the induction
of mesothelin-specific CTL response in combined mAb
treated mice.
Combined treatment of anti-PD-1/GITR mAb and
chemotherapeutic drugs induced a durable antitumor effect
To mimic clinical application more closely, we evaluated
whether anti-PD-1/GITR mAb could synergize with
cisplatin and paclitaxel, two commonly used chemo-
therapeutic drugs for advanced EOC, to produce durable
antitumor effects. We treated ID8 tumor-bearing mice
with i.p. injection of a dose of cisplatin or paclitaxel
1 day before three doses of anti-PD-1/GITR mAb within
a week (Figure 5A). Similar to the result in Figure 1C,
combined anti-PD-1/GITR mAb treatment significantly
prolonged the survival of mice with 20% of mice
remaining tumor-free 90 days after tumor challenge, and
cisplatin or paclitaxel pretreatment alone also modestly
increased the survival of mice; strikingly, combined treat-
ment of anti-PD-1/GITR mAb plus cisplatin or paclitaxel
produced an impressing antitumor effect, resulting in the
long-term survival of more than 80% mice (8 or 9 mice
out of 10 for anti-PD-1/GITR/cisplatin or anti-PD-1/
GITR/paclitaxel respectively) at the terminate of experi-
ments (Figure 5B). With regard to treatments combining
single mAb with chemotherapeutic drug (anti-PD-1/
cisplatin, anti-PD-1/paclitaxel, anti-GITR/cisplatin, or anti-
GITR/paclitaxel), we observed a similar antitumor effect as
treatment with combined anti-PD-1/GITR mAb alone (data
not shown).
To validate the above results, we repeated an experi-
ment with the 4 T1 breast cancer model. BALB/c mice
with s.c. established 4 T1 tumors (4-6 mm in diameter)
were injected i.t. with anti-PD-1/GITR mAb, cisplatin,
paclitaxel or a combination of mAb and cisplatin or
paclitaxel, using the same dose/schedule as in the ID8
experiment. As shown in Figure 5B and 5C, combined
anti-PD-1/GITR mAb exhibited a similar antitumor effect
in this model with evident prolongation of overall survival
(median survival 43 vs 25 days, p < 0.05 compared with
control), however, all mice succumbed to tumor growth
and died by 60 days after tumor challenge. A dose of
cisplatin or paclitaxel alone exhibited a mild antitumor
effect (median survival 29 or 31 vs 25 days). In contrast, a
combination of anti-PD-1/GITR mAb with cisplatin or
Figure 3 Functional analysis of IFN-γ production in tumor-associated CD4+ and CD8+ T cells from treated mice. Mice (5 mice/group)
were transplanted i.p. with 5 × 106 ID8 cells on day 1 and treated with 250 μg of control, anti-PD-1, anti-GITR and anti-PD-1/GITR mAb on day 8,
11 and 15. Seven days after last mAb injection, tumor-associated CD4+ and CD8+ T cells from peritoneal cavity of treated mice were dissected of
IFN-γ production by intracellular cytokine staining. The frequencies of IFN-γ-producing cells in tumor-associated CD4+ and CD8+ T cells are shown
in A. The representative dotplots are shown in B with upper and bottom panels displaying IFN-γ staining in gated CD4+ and CD8+ T cells respectively.
Data are representative of 2 independent experiments, **P < 0.01.
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of mice (4 mice out of 5) survived tumor-free when the
experiment was terminated 90 days after tumor challenge.
These long-term surviving mice developed a systemic
immune response with memory as demonstrated by their
resistance to rechallenge with 4 T1 cells (data not shown).
Discussion
The antitumor effect of immunotherapy remains insuffi-
cient to achieve long-lasting clinical responses in patientswith advanced EOC. In this study, we show that combined
anti-PD-1/GITR mAb elicited a potent antitumor immune
response resulting in significant tumor growth suppression
in a highly clinically relevant ovarian cancer model; more
importantly, anti-PD-1/GITR mAb show a clearly syner-
gistic antitumor effect with cisplatin and paclitaxel, two
most commonly used chemotherapeutic drugs for EOC
patients, in murine ID8 ovarian cancer (C57BL/6 origin)
and 4 T1 breast cancer (BALB/c origin) models with two
strains of mice with different genetic backgrounds. Our
Figure 5 Combined treatment of anti-PD-1/CD137 mAb and chemotherapeutic drugs induced complete remission of established
tumors. A, The experimental schematic: mice (10 mice/group) were transplanted i.p. with 5 × 106 ID8 cells (B) or s.c. with 5 × 105 4 T1 cells
(C and D) on day 1 and were pretreated with a dose of cisplatin (10 mg/kg) or paclitaxel (10 mg/kg) on day 8 and followed by three doses of anti-PD-
1/GITR mAb (250 μg/mice) on day 9, 12 and 16. The mice were treated with PBS, cisplatin, paclitaxel or anti-PD-1/GITR mAb alone as controls. B, The
overall survival of mice in the ID8 cancer model. C, The tumor growth curve in the 4 T1 breast cancer model. D, The overall survival of mice in the
4 T1 breast cancer model. Data are representative of 2 independent experiments. *P < 0.05, ***P < 0.001, compared to control-treated mice.
Figure 4 Treatment with anti-PD-1/GITR mAb induced a tumor antigen-specific CTL response in treated mice. A, Mice (5 mice/group)
were transplanted i.p. with 5 × 106 ID8 cells on day 1 and treated with 250 μg of control, anti-PD-1, anti-GITR and anti-PD-1/GITR mAb on day 8,
11 and 15. Seven days after last mAb injection, splenocytes from treated mice were cultured in the presence or absence of H-2Db-restricted
mesothelin or control GP33-41 epitope peptide for 3 days and IFN-γ production in the supernatants were determined by ELISA. B, Pooled splenocytes
(5 × 106) from control or combined anti-PD-1/GITR mAb were incubated with 5 × 105 UV-irradiated ID8 cells for 4 days prior to subject to analysis of
antigen-specific CTL activity by CytoTox 96 Non-radioactive cytotoxicity assay using EL4 cells pulsed with H-2Db-restricted mesothelin as target cells.
C, As a specific control, pooled splenocytes were tested cytotoxicity against EL4 target cells pulsed with control H-2Db-restricted GP33-41 peptide.
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combination strategy to clinic.
We defined the immune mechanisms of the thera-
peutic effects by combined anti-PD-1/GITR mAb. Ana-
lyzing the components of TAC from treated mice, we
found that single GITR triggering slightly increased or
decreased the percentages of CD4+ and CD8+ T cells or
Treg and MDSC respectively in this tumor model, which
is consistent with previous reporting effects of GITR
triggering on these subsets [31,32]; although single PD-1
blockade had little effect on the components of TAC,
combining PD-1 blockade with GITR activation signifi-
cantly promoted the accumulation of CD4+ and CD8+ T
cells with concomitant attenuation of Treg and MDSC,
giving rise to a favorable ratio of the effector T cells to the
immunosuppressive cells which is closely correlated with
the effective immunotherapy as previously stated [33,34].
Furthermore, increased frequencies of CD44+CD62L-
effector/memory and/or CD44+CD62L+ central memory
cells were present in CD4+ and CD8+ T cells from com-
bined mAb treated mice and these effector or memory T
cells produced much more IFN-γ in response to TCR
engagement. Consistent with these observations, CD4+
and CD8+ T cells were indispensable for tumor protection
conferred by combined treatment as shown in cell
depletion experiments and long-lasting memory immune
response was developed as evidence by the resistance to
tumor rechallenge. The data support that combined PD-1
blockade and GITR triggering shifted an immunosuppres-
sive tumor environment to an immunostimulatory state,
which favorably contributes to a durable antitumor effect.
We detected a systemic antigen-specific CTL response
to ID8-expressing mesothelin in anti-PD-1/GITR mAb
treated mice, as evidenced by mesothelin-specific IFN-γ
production and cytolysis by CD8+ T cells from these
mice. We also observed an increased percentage of
splenic CD8+ T cells in combined mAb-treated mice
compared with that in control or single mAb-treated
mice (9.3 ± 3.1%, 10.3 ± 2.9%, 10.6 ± 3.0% or 13.1 ± 2.6%
for control, anti-PD-1 or anti-OX40 or anti-PD-1/OX40
group); after normalization to the percentage of splenic
CD8+ T cells, a significantly increased mesothelin-
specific IFN-γ production from combined mAb-treated
mice was still seen (data not shown). As an endogenous
non-mutated antigen, mesothelin should be naturally
tolerized against; therefore, the induction of mesothelin-
specific CTL response by anti-PD-1/GITR mAb treat-
ment indicates that endogenous tolerance to mesothelin
was broken, which is consistent with previous studies
demonstrating the overcome of tolerance/ignorance by
GITR activation in murine tumors and the presence of
mesothelin-specific immune response in patients with
cancers expressing high level of mesothelin [24,35,36].
We did not detect mesothelin-specific antibodies insera from mice treated with combined mAb (data not
shown).
Currently, it remains unclear for the mechanisms
underlying the synergy between anti-PD-1 and anti-
GITR mAb. The insensitivity of ID8 ovarian cancer to
treatment of single anti-PD-1 or anti-GITR mAb is in
part due to lack of expression of PD-1 ligands PD-L1/2
or GITR ligand GITRL since ligand expression on the
tumor has been reported to be correlated with the
response to these mAbs [19,37]. We checked the PL-L1
expression on ID8 tumor cells after in vivo treatment by
anti-GITR mAb and found de novo PL-L1 expression on
these tumor cells (Additional file 1: Figure S1), which
may be partially responsible for the resistance of ID8
tumors to treatment with single anti-GITR mAb and
provide a rationale for the synergistic effect of PD-1
blockade and GITR activation in ID8 tumor inhibition.
In addition, GITR triggering may attenuate the Treg-
mediated suppression of antitumor immunity [32] while
PD-1 blockade can release the brake of negative signal-
ing on effector functions of preexisting tumor-associated
T cells. By incorporating those two stings of power, com-
bined treatment of anti-PD-1/GITR mAb can mount a
potent antitumor immunity. Clearly, more studies are
warranted to define further the synergistic mechanisms
in this scenario.
Importantly, addition to the anti-PD-1/GITR mAb
combination of cisplatin or paclitaxel, two commonly
used chemotherapeutic drugs for EOC treatment [38],
administered at a dose equivalent to those used clinically
[39], provided long term remission in more than 80% of
the treated mice. This therapeutic effect was confirmed
in the murine 4 T1 breast tumor model with long-term
survival 4 of 5 mice receiving combined mAb/cisplatin
or paclitaxel treatment. Interestingly, combination of
either anti-PD-1 or anti-GITR mAb and chemotherapeu-
tic drugs did not eradicate most of tumor, underscoring
the necessity of synergistic PD-1 blockade and GITR
triggering in eliciting an optimal antitumor effects. The
detailed mechanisms of synergy between cisplatin/pacli-
taxel and combined immunotherapy remain unclear; how-
ever, increasing tumor antigenicity and/or further deleting
immunosuppressive cells by chemotherapeutic drugs may
be at least partially responsible for their synergism [40].
Future work is needed to elucidate the exact mechanism
of action in this context.
With regard to GITR activation, a clinical grade of
anti-GITR agonistic mAb is being tested in a phase I
clinical trial [28], and GITRL fusion proteins have also
shown a promising antitumor potential in preclinical
tumor models [25]. In the aspect of blocking the inhibi-
tory PD-1 pathway, PD-1- or PD-L1-targeting antagonistic
mAbs have displayed an impressive antitumor effect for
the treatment of advanced solid tumors with manageable
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that consequential peritoneal administration of che-
motherapeutic drugs and mAbs, a procedure that can
be applied clinically in patients with ovarian cancer,
did not induce any obvious toxicity such as weight or
hair loss in this study. Therefore, our findings provide
a strong rationale for clinical trials testing chemo-im-
munotherapy of ovarian cancer by combined PD-1 block-
ade using PD-1- or PD-L1-targeting mAb and GITR
activation using GITR-specific mAb or GITRL fusion pro-
tein and chemotherapeutic drugs.Conclusions
To our knowledge, this is the first study showing that
combinatorial PD-1 blockade by an antagonistic mAb
and GITR triggering by an agonistic mAb induce a
potent antitumor effect, which further synergizes with
commonly used chemotherapeutic drugs in two murine
tumor models. Our demonstration of a synergistic anti-
tumor effect of combining anti-PD-1/GITR mAbs with
chemotherapeutic drugs should stimulate further studies
to assess the safety and efficacy of similar combinatorial
strategies towards ‘translation’ to the clinic.Additional file
Additional file 1: Figure S1. PD-L1 expression on ex vivo ID8 tumor
cells. A, PD-L1 expression on in vitro culture ID8 tumor cells was analyzed
by flow cytometry using PE conjugated anti-PD-L1 (clone MIH5) or
isotype control (clone eBR2a; rat IgG2a) mAb (all from eBioscience). Filled
gray line indicates isotype control staining, and red line indicates PL-L1
staining. B, B6 mice were injected i.p. with 5 × 106 ID8 cells and treated
with 250 μg of control or anti-GITR mAb on day 8. Two days later, tumor
cells were collected and PD-L1 expression was analyzed by flow
cytometry as above. Filled gray line indicates isotype control staining,
blue line indicates tumors from control-treated mice, and green line
indicates tumors from anti-GITR-treated mice.
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